Table 4.

ADHD medication by indication (ICD-10.Rev.), substance group, origin, self-rated improvement of conditions treated, tolerance, duration of use and perceived adverse drug reactions (ADRs)

	Total		Boys		Girls
	N*	%*	N*	%*	N*	%*	p Value
	171	100	144	100	27	100
Indications (ICD 10.Rev.)							0.219
Unknown	1	0.6	1	0.7
Severe depressive episode
without psychotic symptoms (F32.2)	1	0.6	1	0.7
Specific reading disorder F81.0	1	0.6	1	0.7
Disturbance of activity and attention (F90.0)	149	87.1	125	86.8	24	88.9
Hyperkinetic disorder, unspecified (F90.9)	3	1.8	3	2.1
Combined vocal and multiple
motor tic disorder (de la Tourette) (F95.2)	1	0.6	1	0.7
Other specified behavioural and
emotional disorders with onset usually occurring
in childhood and adolescence (F98.8)	3	1.8	3	2.1
Epilepsy, unspecified (G40.9)	1	0.6	0		1	3.7
Malaise and fatigue (R53)	11	6.4	9	6.3	2	7.4
Medicine (ATC code)							0.826
Amfetamine (N06BA01)	3	1.8	2	1.4	1	3.7
Dexamfetamine (N06BA02)	1	0.6	1	0.7
Methylphenidate (N06BA04)	160	93.6	135	93.8	25	92.6
Atomoxetine (N06BA09)	7	4.1	6	4.2	1	3.7
Origin of the medicine
Prescription	171	100	144	100	27	100
Duration of use							0.344
<1 week	11	6.4	9	6.3	2	7.4
1−<4 weeks	22	12.9	21	14.6	1	3.7
1−<12 months	63	36.8	50	34.7	13	48.1
>=1 year	75	43.9	64	44.4	11	40.7
Missing
Self-rated improvement of conditions treated							0.944
Great	98	59.4	83	57.6	15	55.6
Partial	57	34.5	48	33.3	9	33.3
Little	6	3.6	5	3.5	1	3.7
Missing	10		8		2
Tolerance for the medicine							0.860
Very good/good	151	88.8	126	87.5	25	92.6
Partial	16	9.4	14	9.7	2	7.4
Not good	1	0.6	1	0.7
Poor	2	1.2	2	1.4
Missing	1
Perceived ADR	21	12.3	19	13.2	2	7.4	0.317
Amfetamine (N06BA01)	1	0.6	1	0.7
Methylphenidate (N06BA04)	19	11.1	17	11.8	2	7.4
Atomoxetine (N06BA09)	1	0.6	1	0.7

*N and % unweighted.

ADHD, attention-deficit hyperactivity disorder; ATC, Anatomical Therapeutic Chemical; ICD, International Classification of Diseases.